[HTML][HTML] The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review

R Burgos-Pol, JM Martínez-Sesmero… - Actas Dermo …, 2016 - Elsevier
Introduction While the introduction of biologics has improved the quality of life of patients
with psoriasis and psoriatic arthritis, it may have increased the economic burden of these …

Simplified scale for medication adherence related problems in anti-retroviral therapy

JM Ventura-Cerdá, C Mínguez-Gallego… - … : Organo Oficial de …, 2006 - europepmc.org
Objective The purpose is to describe an own-developed scale for medication adherence
evaluation of HIV patients under antiretroviral therapy, and to compare it with other …

[HTML][HTML] Escala simplificada para detectar problemas de adherencia (ESPA) al tratamiento antirretroviral

JM Ventura-Cerdá, C Mínguez-Gallego… - Farmacia …, 2006 - Elsevier
Objetivo Se describe una escala simplificada para detectar problemas de adherencia
(ESPA) al tratamiento antirretroviral en pacientes VIH+ y se compara con otros métodos …

[PDF][PDF] Adherencia en pacientes en tratamiento crónico: resultados del" Día de la Adherencia" del 2013

O Ibarra Barrueta, R Morillo Verdugo… - Farmacia …, 2015 - SciELO Espana
IBARRA BARRUETA, Olatz et al. Adherencia en pacientes en tratamiento crónico:
resultados del" Día de la Adherencia" del 2013. Farm Hosp.[online]. 2015, vol. 39, n. 2, pp …

Coste de la psoriasis y artritis psoriásica en cinco países de Europa: una revisión sistemática

R Burgos-Pol, JM Martínez-Sesmero… - Actas Dermo …, 2016 - Elsevier
Introducción La introducción de las terapias biológicas ha mejorado la calidad de vida de
los pacientes con psoriasis y artritis psoriásica, aunque podría haber incrementado su carga …

[HTML][HTML] Percepción de los profesionales sanitarios sobre la profilaxis preexposición al VIH en España (Estudio PERPPRES)

J Sánchez-Rubio Ferrández… - Farmacia …, 2016 - SciELO Espana
Objective: To determine the level of support, knowledge and perceptions of pre-exposure
prophylaxis (PrEP) by Infectious Disease Specialists and Hospital Pharmacists in Spain …

Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment

B Guglieri-Lopez, JM Ventura-Cerdá… - Enfermedades …, 2014 - europepmc.org
Methods An analysis was made on the data recorded on patients who started treatment with
TVR or BOC associated with peginterferon alfa and ribavirin in a 12-week follow-up period …

Effectiveness of Antiviral Therapy for Genotype 1 Chronic Hepatitis C in Real-World Patients from the Valencian Community (Spain)

L Buigues-Pastor, JM Ventura-Cerdá… - Value in …, 2016 - valueinhealthjournal.com
Objectives To complement the existing studies about effectiveness of antiviral therapy for
genotype 1 chronic hepatitis C by using real-world patients. Methods The effectiveness was …

CP-162 Effectiveness and safety of pirfenidone in idiopathic pulmonary fibrosis

J Martínez-Moreno, AA López-Navarro… - 2016 - ejhp.bmj.com
Background Idiopathic pulmonary fibrosis (IPF) is a fatal pulmonary disease with few
therapeutic alternatives. Pirfenidone is the first drug that has shown clinical benefit in mild to …

PS-072 Incidence, management and cost of Telaprevir/Boceprevir-Induced thrombocytopenia during the first 12 weeks of treatment in patients with hepatitis C

S Gómez-Álvarez, B Guglieri-López, J Ventura-Cerdá… - 2015 - ejhp.bmj.com
Background Protease inhibitor-based triple therapy increases the expected incidence and
severity of haematological adverse events, with repercussions on the total cost. Purpose To …